EP1309722A1 - Use of microbial dna sequences for the identification of human diseases - Google Patents
Use of microbial dna sequences for the identification of human diseasesInfo
- Publication number
- EP1309722A1 EP1309722A1 EP01902591A EP01902591A EP1309722A1 EP 1309722 A1 EP1309722 A1 EP 1309722A1 EP 01902591 A EP01902591 A EP 01902591A EP 01902591 A EP01902591 A EP 01902591A EP 1309722 A1 EP1309722 A1 EP 1309722A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- gene
- mutation
- anyone
- protein
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 22
- 230000000813 microbial effect Effects 0.000 title claims abstract description 22
- 201000010099 disease Diseases 0.000 title claims abstract description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 11
- 241000282414 Homo sapiens Species 0.000 title claims description 37
- 239000000304 virulence factor Substances 0.000 claims abstract description 20
- 230000007923 virulence factor Effects 0.000 claims abstract description 19
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 10
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims abstract description 8
- 239000012634 fragment Substances 0.000 claims abstract description 5
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 4
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 84
- 101150066912 Cbl gene Proteins 0.000 claims description 48
- 230000035772 mutation Effects 0.000 claims description 46
- 241000589968 Borrelia Species 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 230000008488 polyadenylation Effects 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 21
- 239000013612 plasmid Substances 0.000 claims description 20
- 201000000980 schizophrenia Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 241000224016 Plasmodium Species 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 12
- 230000009261 transgenic effect Effects 0.000 claims description 12
- 241000606161 Chlamydia Species 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 11
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 206010012289 Dementia Diseases 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 8
- 230000033228 biological regulation Effects 0.000 claims description 7
- 108010036908 Presenilin-2 Proteins 0.000 claims description 6
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 108091036066 Three prime untranslated region Proteins 0.000 claims description 5
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000002779 inactivation Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 4
- 101710121290 Oligophrenin-1 Proteins 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 238000013519 translation Methods 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 241000606701 Rickettsia Species 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 101150070366 2C gene Proteins 0.000 claims description 2
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 claims description 2
- 241000488157 Escherichia sp. Species 0.000 claims description 2
- 101710180845 Integral membrane protein 2B Proteins 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 claims description 2
- 230000007119 pathological manifestation Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108091036407 Polyadenylation Proteins 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000007614 genetic variation Effects 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 3
- 238000010171 animal model Methods 0.000 abstract description 2
- 208000016604 Lyme disease Diseases 0.000 description 39
- 241000589969 Borreliella burgdorferi Species 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 25
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 22
- 230000002068 genetic effect Effects 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 230000037431 insertion Effects 0.000 description 11
- 238000005215 recombination Methods 0.000 description 8
- 230000006798 recombination Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 241000589970 Spirochaetales Species 0.000 description 7
- 108060003196 globin Proteins 0.000 description 7
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 102000018146 globin Human genes 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 102000012419 Presenilin-2 Human genes 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000000698 schizophrenic effect Effects 0.000 description 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 4
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 4
- 241000223960 Plasmodium falciparum Species 0.000 description 4
- 208000035415 Reinfection Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 101150045801 ospA gene Proteins 0.000 description 4
- 208000023697 ABri amyloidosis Diseases 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 241000218236 Cannabis Species 0.000 description 3
- 101150049660 DRD2 gene Proteins 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 208000004547 Hallucinations Diseases 0.000 description 3
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 3
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 3
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000033607 mismatch repair Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 241001148605 Borreliella garinii Species 0.000 description 2
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 2
- 208000010482 CADASIL Diseases 0.000 description 2
- 108050007331 Cannabinoid receptor Proteins 0.000 description 2
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 description 2
- 241001647367 Chlamydia muridarum Species 0.000 description 2
- 101100385572 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) ctfA gene Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 206010012239 Delusion Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000794024 Homo sapiens Bromodomain-containing protein 4 Proteins 0.000 description 2
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 2
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 description 2
- 108010029756 Notch3 Receptor Proteins 0.000 description 2
- 101710105714 Outer surface protein A Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 206010043391 Thalassaemia beta Diseases 0.000 description 2
- 208000002903 Thalassemia Diseases 0.000 description 2
- 102000002501 Tryptophan-tRNA Ligase Human genes 0.000 description 2
- 108700016206 Tryptophan-tRNA ligases Proteins 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000011142 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 Diseases 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 231100000868 delusion Toxicity 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 244000000056 intracellular parasite Species 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 101150092010 lpl7 gene Proteins 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 210000003936 merozoite Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 101150055083 ospC gene Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 208000026833 Alzheimer disease 4 Diseases 0.000 description 1
- 208000000340 Alzheimer disease type 1 Diseases 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 108010054473 Bacteria oligopeptide permease Proteins 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 206010061591 Borrelia infection Diseases 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241001495184 Chlamydia sp. Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193454 Clostridium beijerinckii Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102100025709 Dyslexia-associated protein KIAA0319 Human genes 0.000 description 1
- 102000008013 Electron Transport Complex I Human genes 0.000 description 1
- 108010089760 Electron Transport Complex I Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101100394050 Escherichia coli (strain K12) gyrB gene Proteins 0.000 description 1
- 101000783609 Homo sapiens 5-hydroxytryptamine receptor 1E Proteins 0.000 description 1
- 101001056599 Homo sapiens Dyslexia-associated protein KIAA0319 Proteins 0.000 description 1
- 101000637249 Homo sapiens Nexilin Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000708766 Homo sapiens Structural maintenance of chromosomes protein 3 Proteins 0.000 description 1
- 101000963221 Homo sapiens mRNA guanylyltransferase Proteins 0.000 description 1
- 101150102264 IE gene Proteins 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100031801 Nexilin Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102100035592 Oligophrenin-1 Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710105711 Outer surface protein C Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 102100022036 Presenilin-2 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108030005599 Pseudouridylate synthases Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 241000606697 Rickettsia prowazekii Species 0.000 description 1
- 101100482715 Streptomyces triostinicus trsA gene Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 208000010206 X-Linked Mental Retardation Diseases 0.000 description 1
- 101150004068 acrB gene Proteins 0.000 description 1
- 229940023020 acriflavine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007924 bacterial virulence factor Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 102100039604 mRNA guanylyltransferase Human genes 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001343 mnemonic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108010078587 pseudouridylate synthetase Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 101150075203 ral gene Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 229940046939 rickettsia prowazekii Drugs 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 108010030336 serotonin 1E receptor Proteins 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 208000031906 susceptibility to X-linked 2 autism Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 201000006088 tertiary neurosyphilis Diseases 0.000 description 1
- 101150079911 traJ gene Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 101150059846 trpS gene Proteins 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to the use of a DNA sequence comprising a fragment of a nucleic acid encoding a microbial virulence factor as means for the identification of a disease or a genetic predisposition thereof as well as its use for the development of disease animal models .
- virulence factor stems preferably from a intracellular microorgansim and is located on a linear or circular chromosome or a plasmid, more preferably said virulence factor stems from a microorganism which is selected from the group consisting of Borrelia species, Chlamydia sp., Escherichia sp., Plasmo- dium sp. and Rickettsia.
- nucleic acid encoding a virulence factor is selected from the group consisting of Seq. Id. No. 1 to Seq. Id. No. 17.
- Virulence factors stemmming from non-intracellular microorganisms which are part of a cluster shared by intracellular microonganisms are as well suitable for the use in the present invention.
- Another object of the present invention is a method for the identification of a disease or a genetic predisposition thereof, which comprises in a tissue or blood sample of a subject or in a fetal neuro-graft a mutation within a nucleic acid sequence selected from the group consisting of Seq. Id. No. 1 to Seq. Id. No.
- said sequence is inserted in a gene of said subject.
- said sequence is inserted in the 3'UTR of said gene and said mutation is found in the polyadenylation signal of said gene and said mutation preferably affects the expression of the protein encoded by said gene.
- transgenic non-human animals which comprise in their ge- no e a partial or complete inactive endogenous gene which is selected from the group consisting of cannabinoid receptor 1 gene, MAP 2C gene, apolipoprotein E gene, prese- nelin 2 gene, integral membrane protein 2B gene, alpha synuclein gene, oligophrenin 1 gene and myotonin protein kinase gene.
- the gene is inactivated due to at least one mutation in its 3' untranslated region (3' UTR) and said mutation leads to an inhibition or suppression of protein expression.
- the term mutation as used herein encompasses any nucleotide change, insertion or deletion independent of their length that influences the activity, expression or regulation of a gene.
- any mutation in the 3'UTR region leading to an inhi- bition or suppression of protein expression e.g. CBl protein expression
- Any mutation in the polyadenylation signal sequence leading to an inactivation of said signal can be used.
- the mutation can e.g.be caused by a sequence of the same or a different microbial species e.g. by gene conversion or recombination.
- the polyadenylation signal in eukaryotes has the following conserved sequence: AATAAA.
- any non-human mammal can be used.
- rodents e.g. mice or rats, which preferably harbor a homozygous or heterozygous CBl gene inactivation in their genome.
- Another object of the present invention is the use of the transgenic animals of the present invention for the identification of compounds that have an effect on the activity, expression or regulation of the gene encoded protein.
- the animals of the present inven- tion allow the identification of compounds which have a direct or indirect effect on CBl protein, MAP 2C protein, Apolipoprotein E, presenilin 2 protein, integral membrane
- Figure 1 shows genetic exposure triggering gene conversion and further infectious recombination
- Figure 2a shows genetic exposure leading to multiple translocations into the human genome
- Figure 2b shows genetic exposure leading to multiple translocations into the human genome .
- a gene construct for the production of a transgenic animal of the present invention which comprises in its genome a partially or completely inactivated gene, can be prepared using standard genetic engi- neering technologies known in the art, such as described in Maniatis et al . , Molecular cloning: A Laboratory Manual, Cold Spring Laboratory, Cold Springs Harbor, N.Y.
- the starting material for said construct can be a portion of e.g. the genomic or cDNA CBl nucleotide sequence.
- In- troduction of the wanted mutation in e.g. the CBl sequence can be done by methods known to a person skilled in the art e.g. by site directed mutagenesis.
- the term mutation as used herein encompasses any nucleotide change, insertion or deletion independent of their length that influence the activity, expression or regulation of a gene .
- a transgenic animal in accordance with the present invention can be made using generally known methods in the field. See, for example, Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986), Knock-out mouse models used to study neurobiological systems, Critical Reviews in rt ⁇ - ⁇ J tr ⁇ rt o ⁇ - CO rt Hi > ⁇ ! rt O ⁇ rt rt 0 3 rt tr 3 OJ to us Pi en ⁇ OJ en Hi tQ TJ g
- the present invention also concerns methods for the identification of a disease caused by bacterial mutations or a genetic predisposition thereof.
- Said methods comprise detecting the presence in a tissue-or blood sample of a subject a muta- tion within a nucleic acid sequence selected from the group consisting of Seq. Id. No .1 to Seq. Id. No. 17 and said sequence is part of a gene of said subject.
- the method of the present invention is e.g. suitable for the identification of one of the above mentioned diseases.
- Suitable methods for the identification of said diseases or a genetic predisposition thereof in humans are for example PCR techniques, DNA or gene chips, hybridisation techniques and Ligases chain reaction (LCR) .
- said method comprises the following steps:
- the sequencing step allows the identification of mutations present in the insertion sequence of interest.
- the design of the oligonucleotide primers is known to those skilled in the art and can be done using standard software. Examples
- Microbial sequences in 3'UTR polyadenylation regions of schizophrenia and dementia genes harbour microbial virulence factors and plasmids
- DNA from Borrelia burgdorferi , Chlamydia and other intracellular microbes has inserted into ancestral 3 ' polyadenylation sites of the following candidate neu- rological genes: The central cannabinoid receptor gene (CBl) , Alzheimer disease and other dementia genes, Parkinson disease and myotonic dystrophy (see Seq. Id. No. 1 to 17 and Table 1A to IE) . Most insertions originate from microbial virulence factors, transposable elements and plasmids .
- CBl and 5HT1E contain related insertions from B. burgdorferi .
- the human CBl gene is located at 6ql4, which has been reported as a candidate region for schizophrenia involving a translocation break-point co- segregating with schizophrenia, immediately adjacent to the 5-hydroxytryptamine (5HT1E) gene.
- the spirochaetal insertion into 5HT1E originated from a B . burgdorferi virulence factor, the flagellar basal-body rod protein (fbrp) , responsible for chemotaxis, locomotion and a sy- ringe mechanism for injection into cells. Through infectious recombination, B .
- burgdorferi introduced another nucleotide sequence containing pll5 and a polyadenylation site into our ancestral genome.
- pll5 overlaps with fbrp.
- the fbrp section on the CBl gene originates from an ancient 5HT1E receptor already containing the spirochaetal insertion and not from a direct transposition of B . burgdorferi onto 6ql4, because the first three nucleotides of the overlapping sequence (see Table 1A) are on 5HT1E, and not on fbrp of B . burgdorferi .
- Gene conversion is the most likely explanation since CBl and human 5HT1E, on which fbrp is absent, are both located in tandem on 6ql4. OJ OJ t to I- 1 I- 1
- the transition of the parasite from arthropod vector to human host is accompanied by significant changes in gene expression, which has practical relevance for prevention, as well.
- the recently approved vaccine against Lyme disease consists of an immunogenic Osp A, that is expressed by the spirochaetal parasite while in the tick gut, turned off on entry into humans and then expressed again at a late chronic stage. After attachment of an infected tick and initiation of a blood meal, anti-OspA antibodies enter the tick gut and mediate killing of B . burgdorferi .
- pll5 thus introduced the code for the translation and actual genetic ex-pression of CBl.
- B. burgdorferi appears to be excluded from the benefits of the extensive lateral gene transfer between micro-organisms, however, as an intracellular parasite with an incomplete genome B. burgdorferi has a direct access to host genes, which it exploits for replication, and not to be recognised as foreign, the spirochete depends on its own sequences within the human genome.
- B. burgdorferi might, for example, dispose of a protective shield at the DNA and protein level, respectively.
- Dissimilarity and mismatch mutations between B . burgdorferi and its pre-inserted human templates may nevertheless occur, resulting from genetically induced variability by virulence factor operons, osp A and B, or, alternatively, from a genomic decay in plasmids (Casjens et al., Mol. Microbiol. 2000, 35, 490-516) borrelia reinfection causing putative mutations in AATAAA. Intrigu- ingly, by a single frame-shift mutation within the original translocase, the same process of genomic decay has apparently incapacitated B . burgdorferi to translocate further genetic templates into its hosts (Casjens et al . , Mol. Microbiol.
- Dissimilarity and infectious recombination between protein coding sequences of the human chromosome associated protein hCAP and borrelia P115 could, on the other hand, account for the altered leukocyte chromatin ultra-structure reported in schizophrenic patients.
- homologous proteins comprise G-protein coupled receptors that receive information from outside the cell, such as olfaction or vision.
- D2 dopamine 2 receptor
- D2 dopamine 2 receptor
- Identities 19/19 (100%) .
- the circumscribed homology between CBl and the D2 receptor which is an important phar acol- ogical target for the treatment of schizophrenia, encodes the seventh transmembrane loop which is known for its inhibitory-mode (i-mode) of metabotropic action.
- i-mode inhibitory-mode
- this homologous nucleotide sequence can be found an all sequenced primate (Macaca mulatta, Cercopithecus aethiops, H. sapiens; OMIM, 2000) and rodent (Mus muscu- lus) D2 receptor genes.
- dementia praecox schizophrenia
- syphilitic de- mentia The difference between dementia praecox (schizophrenia) and syphilitic de- mentia is that without memory hallucinations are lost, and that the thoughts of schizophrenics are flooded with fixed hallucinations, expanding into overt delusions.
- CBl knock-out mice do show reduced exploratory, goal-directed behaviours (Steiner et al . Proc. Natl. Acad. Sci. USA, 2000, 96, 5786-5790); symptoms that appear to be among the most robust indices in schizophrenia. Without time-bridging working memory, no creative speech and no logical thinking would be possible.
- the phylogenetic traces of microbial insertions into the human genome were investigated and the gene- tic mechanism were analysed, by which bacterial virulence factors and mobile elements from intracellular parasites could disrupt candidate genes for schizophrenia and dementia. This was done by co-incident DNA homology BLAST searches between neurotropic microorganisms, the central cannabinoid receptor CBl, and other known dementia genes, whose complete sequences with 3'UTR and polyadenylation signals are entered on Gene-Bank databases. Several such genes have now been characterised including those of ApoE4 Alzheimer Disease type II (AD2) and presenilin 2 (AD 4) .
- AD2 ApoE4 Alzheimer Disease type II
- AD 4 presenilin 2
- Positional cloning and sequencing has also been carried out in other dementias including Familial British Dementia (with mutations in the gene for integral membra- ne protein 2A) , Hereditary Multi-infarct Dementia (Notch- 3 gene) , primary X-linked mental retardation (oligo- phrenin 1 gene) , Frontotemporal Lobe Dementia, Autosomal Dominant Parkinson Lewy-Body Dementia and Familial Par- kinson disease type I (with mutations in the alpha synuclein gene) .
- the genomic facilities used are accessible at Online Mendelian Inheritance of Man (OMIM) and very much recommended to anybody interested in applied medical genetics . While there are shown and described presently preferred embodiments of the invention, it is to be distinctly understood that the invention is not limited thereto but may be otherwise variously embodied and practiced within the scope of the following claims.
- Chlamydia integration into ancestral rodent CBl Chlamydia (8221) TTACCTGGACTCAAATAAAAGT(8242) 3 ' 20
- Chlamydia (8219) AGTTACCTGGACTCAAATAAA ( 8240 ) 3 ' 2
- AMYLOID PRECURSOR PROTEIN Alzheimer's disease type 1 (protease nexin-II)
- Plasmodium chromosome 3 (79642) TTTTCATGTAAATAAATA (79625)5' 6
- FAMILIAL BRITISH DEMENTIA (xntegral membrane protexn 2B gene) Borrelxa burgdorferi Ixnear plasmxds lp25, lp36 and Plasmodium fal ⁇ iparum major merozoite surface & receptor binding protein
- Oligophrenin 1 Oligophrenin 1
- OPHN 1 (6648) CAAATAAAGTAGTAAAAGA (6666) 3 V 56
- FRONTOTEMPORAL LOBE DEMENTIA gene for microtubule associated protein tau
- Escherichia (pilus protein) (860) AATAATAAAAATCATGCTT(878) 3 ' 11
- Mt-PK human myotonxn protein kinase
- Chlamydia (3551) GCGAATAAAAGGCCCT (3536) 5 ' 14
- Rickettsia (232700) AATAAAAAACATTTAT (232685) 5 ' 15 Borrelia (oppAIV) (1143) ATGTATTTAAAT (1132) 5' 41
- Borrelia burgdorferi (pll5) : related to human chromosome associated protein responsible for DNA and intracellular movement .
- lipoprotein P homologous sequences on plasmids, i.e. Ip38, anti-genetic surface protein.
- Borrelia b. (comp. loc) competence locus with multiple homologous copies throughout genome.
- Borrelia b. (sgp) stability governing protein for stabilisation of membrane.
- Borrelia b. (ospC) outer surface protein C; 18 base pair distant from 3' poly-A cleavage site of (globin. Target of Borrelia vaccine.
- Chlamydia muridarum (ibp) within CBl iron binding protein to overcome host barriers of low iron levels .
- Chlamydia m. within Mt-Pk phosphocarrier protein.
- Chlamydia pneumonae hypothetical protein.
- Clostridium beijerinckii small subunit of coenzyme A transferase.
- Escherichia coli pilus protein responsible for cellular adherence and infection.
- Plasmodium bergei within globin series: phosphoprotein mRNA.
- Plasmodium falciparum within CBl rhoptry associated protein (264) ATCAAATAAAAGTTCTA ( 280 ) 3 ' for erythrocyte penetration.
- Plasmodium f . within amyloid precursor protein several sequences form chromosome 3 including hypothetical pro- teins .
- Plasmodium f. (mmsp) major merozoite surface protein, expressed during sexual stage.
- Plasmodium f. Plasmodium falciparum-encoded protein on the surface of infected erythrocytes mediates receptor binding.
- Plasmodium f . in thalassaemia (globin: RNA polymerase III. Rickettsia prowazekii in (globin: proline-betaine transporter for the reduction of osmotic stress in host environment .
- Vibrio cholerae (ntno) Na+-translocating NADH-ubiquinone oxidoreductase enzyme complex involved in flagella rotation.
- Microbial virulence factors within the 3' genetic hotspot of human disease Base pairs originating form the late- ral gene transfer of microbial nucleotides are indicated in upper case, and non-microbial nucleotides in lower case letters. There are normally no point mutations on the polyadenylation signal, whose non-redundant code protects the microbial inclusions from mutations. Homologous recombination between B. burgdorferi pll5 and the bor- relia template fbrp originating from ancestral 5HT1E has introduced the polyadenylation signal AATAAA into CBl. Note that recombinational mismatch-repair has inserted an additional adenine into CBl.
- a point mutation from A to G has through a reduction of the adenine content led to a shortening of the 3' polyadenylation tail of the rat.
- human CBl and rat CBl almost identical, but independent insertions of C. muridarium nucleotides must have occurred twice. This reoccurrence emphasises the attraction CBl and its polyadenylation signal exerts on microbi- al DNA to recombine .
- dissimilarity i.e. AATATA
- mismatch repair mutations might, in analogy to the genetic knock-out of globin in thalassaemia, result in a knock out of CBl and other neurological candidate genes .
- Microtubule associated protein 2C (MAP2C)
- AD2 Alzheimer's diease type 2
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
The use of DNA sequences comprising a fragment of a nucleic acid encoding a microbial virulence factor as means for the identification of diseases or a genetic predisposition thereof as well as its use for the development of disease animal models is disclosed.
Description
Use of microbial DNA sequences for the identification of human diseases
Cross Reference to Related Application
This application claims the priority of PCT patent application IBOO/01127, filed August 16, 2000, the disclosure of which is incorporated herein by reference in its entirety.
Technical Field
The present invention relates to the use of a DNA sequence comprising a fragment of a nucleic acid encoding a microbial virulence factor as means for the identification of a disease or a genetic predisposition thereof as well as its use for the development of disease animal models .
Background Art The functional sequences of higher eukaryotes consist of genetic modules of at least two kinds. Modules of coding sequence are combined in many ways to produce proteins, whereas modules of non-coding sequences regulate the expression of genes. Some of the mutations cre- ated duplicates of entire genes, which have then evolved new functions, while others altered the expression of old genes by exposing them through gene shuffling to new regulatory sequences. By these means the human genome as a whole has evolved to its present day complexity. Since the 3' untranslated region (3'UTR) and especially the polyadenylation signal within the 3 ' UTR regulate the translation and expression of a gene, the entire gamut of molecular perturbations can be accomplished with the 3'UTR as a primary target. There is therefore a need for molecular tools allowing the detection of diseases or a predisposition thereof caused by mutations within the 3' UTR.
Disclosure of the Invention
In the scope of the present invention it was now found that there are microbial DNA insertions in the 3 ' UTR of human genes which are associated with human diseases .
Hence it is an object of the present invention to provide the use of DNA sequences comprising a fragment of a nucleic acid sequence encoding a putative microbial virulence factor as means for the identification of diseases caused by bacterial mutations or a genetic predisposition thereof. The virulence factor stems preferably from a intracellular microorgansim and is located on a linear or circular chromosome or a plasmid, more preferably said virulence factor stems from a microorganism which is selected from the group consisting of Borrelia species, Chlamydia sp., Escherichia sp., Plasmo- dium sp. and Rickettsia. Even more preferably said nucleic acid encoding a virulence factor is selected from the group consisting of Seq. Id. No. 1 to Seq. Id. No. 17. Virulence factors stemmming from non-intracellular microorganisms which are part of a cluster shared by intracellular microonganisms are as well suitable for the use in the present invention. Another object of the present invention is a method for the identification of a disease or a genetic predisposition thereof, which comprises in a tissue or blood sample of a subject or in a fetal neuro-graft a mutation within a nucleic acid sequence selected from the group consisting of Seq. Id. No. 1 to Seq. Id. No. 17 and said sequence is inserted in a gene of said subject. Preferably said sequence is inserted in the 3'UTR of said gene and said mutation is found in the polyadenylation signal of said gene and said mutation preferably affects the expression of the protein encoded by said gene.
Another object of the present invention are transgenic non-human animals, which comprise in their ge-
no e a partial or complete inactive endogenous gene which is selected from the group consisting of cannabinoid receptor 1 gene, MAP 2C gene, apolipoprotein E gene, prese- nelin 2 gene, integral membrane protein 2B gene, alpha synuclein gene, oligophrenin 1 gene and myotonin protein kinase gene. The gene is inactivated due to at least one mutation in its 3' untranslated region (3' UTR) and said mutation leads to an inhibition or suppression of protein expression. The term mutation as used herein encompasses any nucleotide change, insertion or deletion independent of their length that influences the activity, expression or regulation of a gene.
Although in the context of the present invention any mutation in the 3'UTR region leading to an inhi- bition or suppression of protein expression e.g. CBl protein expression, can be used, preferred are mutations located in the sequence following the polyadenylation signal, more preferably in the polyadenylation signal sequence of said gene. Any mutation in the polyadenylation signal sequence leading to an inactivation of said signal can be used. The mutation can e.g.be caused by a sequence of the same or a different microbial species e.g. by gene conversion or recombination.
The polyadenylation signal in eukaryotes has the following conserved sequence: AATAAA.
For the purpose of the present invention any non-human mammal can be used. Preferred are rodents e.g. mice or rats, which preferably harbor a homozygous or heterozygous CBl gene inactivation in their genome. Another object of the present invention is the use of the transgenic animals of the present invention for the identification of compounds that have an effect on the activity, expression or regulation of the gene encoded protein. The animals of the present inven- tion allow the identification of compounds which have a direct or indirect effect on CBl protein, MAP 2C protein, Apolipoprotein E, presenilin 2 protein, integral membrane
H- 9) OJ H- TJ 0 0 Hi Φ 0 rt H- tr Ω en 0J 0J 0J 3 TJ ω 3 TJ O 0J en TJ 3 Ω h rt TJ
0 Ω P H cn H H- 0 0 0J ø en O Φ 0 ø φ øJ φ H Φ 0 Ω 0 0J μ- O φ φ ii
H- rt φ H- φ O- O 0 ft -> (0 H H- ii H- ii H- Or ii 3 O Ω 3 - 0 f-1 tr 3 (Q H- O en 3 H- 0 cn Φ ^ ø H- en 0 < 3 OJ 3 0" Φ ø' rt ft ft φ μ- 0 en TJ ø 0 rt
C- ) < rt φ o Ii Q- H- H- T ø μ- 0J 0J rt 0J 0 0 ii Φ Φ tf ft N i 0J o Φ
H- H H- H- tn Hi en o 3 en 0 0J O Ω tr - H P-. μ- 0J μ- P. Φ tr 0 0 ii 0 0J 0J H- rf rt Hi rt H- <! h-1 Ω ø OJ . ø 0 ø o TJ Hi Hi μ- 0 rt 0 0
OJ O ><; H- PJ OJ tr 0 φ TJ *<; ft φ Φ 0J 0 Ω Φ Hi 0J p. tr o Φ Pi μ- Pi tr 0 ^ n Φ P H 0J H- £ 0 Hi O ÷ O Ω ii ii rt en en o iso
(-■ £ J p. rt ϋ 0" rt Φ & O TJ tr μ- P. 3 TJ l ii rt Hi φ tr ø 3 Cd φ TJ Φ ft H- i 0 H- Hi ffi OJ Hi øJ Φ o ft TJ TJ H TJ 3 μ- O ø rt Φ Φ *< -
£ H- cn 0) Hi 3 O φ 0 rt φ pJ φ 3 PJ ii H O O < H. μ- tr > . o
Hi H- TJ o t-i 0 H o 0) 0 n • ; Φ ft 0 0J o Φ w- o ft H r μ- 0 Φ TJ tQ _. rt 0J
0 CO n 0 ø en 0 H ø 0J P, ' o <! 0J 0 en ft Φ μ- PJ rt en ii Ω • tr O n H- Φ T tQ 3 en tr 0J φ 3 μ- ø μ- TJ φ φ μ- TJ Φ ^ Ω Hi 0 Pi Φ O Φ ø TJ
0 en 0 rt Φ OJ en en H- rt tr φ o ^ rt ϋ en μ- ø o ii 0 ii Φ CO 3 0J μ- ø
OT <Q n H H- £ 3 * H- » OJ ø 0 O (0 ø TJ <Q Φ H <J Φ T CO Ω ø 0J q H- O H- Hi 0 tr Ω O tr 0 ii ii ii en μ- tSJ ii ii Φ Φ ft 0 Φ 0 O 0 o 0) 0 O 0 n 0 Hi l_l. Φ q 0 OJ 0 0J 0J μ- φ ø OJ ω O O !*! ø øJ rt H rt 0 0 3 TJ en tr P o ii Φ en < 0 H rt ø ø rt ø rt ø TJ μ- φ t 0 0 tr TJ H
3 3 O ø ft α Ω en φ en 3 Φ IQ en tQ tt ii Pi Φ TJ ii ø ii φ V, μ- Pi rt o O ø
OJ 0 0 TJ Hi 0 tr φ rt ø P- H- ø Ω 0 0J μ- Φ tQ 3 ø 0J 0 ft q
0 ϋ 0 ø Φ 3 en Ω (Q ft 3 øJ OJ Φ μ- Pi 3 H ø Ω en O φ < μ- μ- ø φ Ω q 1 0 ft 1 H Φ ø- H- ø 0 φ OJ ii ø 0 * T O en Hi tr Hi ø Φ i ø i H- M to Hi i 0 iX 0- 3 en ø OJ rt ø > 0 Φ tQ <! Ω 0 ø' M 0 μ- 0 <_l. 0 rt 0 Φ Φ 0 φ φ £ Φ α Φ d PJ rt C 0J -1 H- rt I • Φ μ- rt 0J en O ii φ ii rt 0 Pi 3 H-
- 0 (Q en 3 en H- Hi
TJ ø 0J o H- rt Φ TJ ø 0 o μ- ø Ω 3 o μ- rt 0J rX ø
O 0 Φ OJ 0J Hi o 0 O ii en ii tr ft (Q en TJ cn Ω rt en Hi O μ- Hi ^ μ-
TJ ft ft φ ø
P 0 en Φ 0J en H 0 0J Φ Φ μ- μ- ^ ii rt o o ø Hi ii ø TJ
H H- P tr P> n ii ø Ω H- Φ 0 OJ Hi 0 o 0J ø ft ø Φ μ- ϋ 3 o 0 3 μ- 0 Ω 0J ii
Φ 0 A) O 0) rt OJ H- H- ϋ H- 0 P en i Φ 0J ø ø en ø T Hi Hi φ Ω Φ 3 O CO O
Hi P H- rt tQ ø ø ø 3 Φ 0 iQ Φ H <! Ω TJ Ω Φ iQ ii 0 . 0J P. 0 φ rt
Φ 0) 0 Φ H- rt Pi tQ 0) Φ ft IP Φ ii μ- 0 ii ø Φ ø rt Pi μ- 0 Ω en Φ
H H> P V 0 3 i-T ø rt f φ 0 Ω Φ o TJ 3 0 φ μ- o tQ 0 ø4 Φ Ω tr o μ- J H-
9) PJ 0 O φ 0 Φ H- øJ Φ 0 H- 0 P 0 H TJ rt μ- Hi ø Pi Φ 3 0J CO ^ en Ω 0 tr O 0 <! rt 0 Φ φ Ω 0 ii Φ 0 Φ ø μ- en φ 3 φ [j* rt ft
H ω Hi Φ en H- 13- tQ Φ iQ en en en 0J 0J Hi 0 μ- ø O 0J TJ ø φ ii rt μ- μ-
■<; s 3 Φ Hi TJ φ 0J H- 0 t-1 Φ 0 ø TJ C rt rt rt ø < tr ø O < O π OJ O tf <! ii 3 0 μ- 0 & μ- ii Pi ii t H1 μ- øJ Φ μ- rt Φ φ 0J Hi μ- ø) tQ Cd 0 rd 0 φ Hi Φ Φ I-1 ■g ø μ- Φ 3 Ω OJ rX O 0 OJ en 0J en rt rt μ- φ l-» en 3 0 ii Ω rt ■<: Φ 3 0) øJ tr μ- μ- rt TJ TJ ø rt Φ . 0J 0 o 0J •< tQ
3 0 Φ Φ rt Φ O rt iX 0J ø H- 0J Φ H4 0J H ø ø φ ii H 0 rt cn en O o Φ TJ Hi iQ H- q 3 en O Ω ft h-> Pα en 0 » 0J μ- O O O øJ rt 0 Φ μ- 3 TJ
0 Hi Φ tQ O ii O. Φ Φ en - (Q 0J en ø rt ft Hi 0J 0J 0J ø Φ tr en H- 0 Φ 3 Φ 3 0 en rt ii 0J Φ μ- ø φ Φ Φ < μ- rt O X φ 3 rt O Φ 0 H4 Ω ' 0 •< Hi ιp Φ en en ø • μ- μ- T Φ 0 ii M Hi rt TJ Φ
Φ ft 0 TJ 0 t Φ Hi H O Φ " rt O 0 ø H < Φ Φ Ω μ- ii ø
0 H- H- Hi 3 i tQ H- l-1 ø μ- Φ rt μ- ii CO H1 O 0J Φ 0J 0J rt tr TJ Φ μ-
H. rt 3 o 0 Φ O H- N en ft ft O Ω ø" ø OJ 0J μ- ft 0 0 rt Pi t-r Φ (-■ en ø to • P Ii < Ω O H- PJ H- O 3 t 0J φ 3 0 μ- iQ μ- g Φ rt φ 3 μ- en
OJ O H- OJ TJ rt Φ O ^ φ 0 μ- en o en Pi O ø ^ μ- Φ μ- Φ Ω μ- Ω μ- μ* tQ rt rt 0 £• H p- q 0 H- PJ rt H 0 £ cQ 1 rt fτj ø Hi o O 0J Ω μ- O
Ii Φ i-T* rX 3 Φ H 0J TJ 0 rt OJ μ- en Φ Φ en Hi 0 tQ 3 0 0J rt ø TJ
OJ ø ^ Φ Φ 1 en P. Φ rt ii en iQ øJ ii rt 0 i Φ ø (Q NJ Φ 1 μ- • ii rt 0 H- 1 H- Φ H- OJ 1 0 tr H- ii O CO Ω μ- 1 o O
• 3 OJ en O en iQ rt 1 O Ω OJ Φ rt en O H 1 φ 1 0 1 1 H. h-1 1 Hi
Brief Description of the Drawings
The invention will be better understood and objects other than those set forth above will become ap- parent when consideration is given to the following detailed description thereof. Such description makes reference to the annexed drawings , wherein :
Figure 1 shows genetic exposure triggering gene conversion and further infectious recombination, Figure 2a shows genetic exposure leading to multiple translocations into the human genome and
Figure 2b shows genetic exposure leading to multiple translocations into the human genome .
Modes for Carrying Out the Invention
A gene construct for the production of a transgenic animal of the present invention, which comprises in its genome a partially or completely inactivated gene, can be prepared using standard genetic engi- neering technologies known in the art, such as described in Maniatis et al . , Molecular cloning: A Laboratory Manual, Cold Spring Laboratory, Cold Springs Harbor, N.Y. The starting material for said construct can be a portion of e.g. the genomic or cDNA CBl nucleotide sequence. In- troduction of the wanted mutation in e.g. the CBl sequence can be done by methods known to a person skilled in the art e.g. by site directed mutagenesis. The term mutation as used herein encompasses any nucleotide change, insertion or deletion independent of their length that influence the activity, expression or regulation of a gene .
A transgenic animal in accordance with the present invention can be made using generally known methods in the field. See, for example, Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986), Knock-out mouse models used to study neurobiological systems, Critical Reviews in
rt μ- ≥J tr ø rt o μ- CO rt Hi > <! rt O Ω rt rt 0 3 rt tr 3 OJ to us Pi en < OJ en Hi tQ TJ g
0 cn OJ μ. Ω tr Hi ø μ- Φ μ- ft OJ H- Cd ii φ Φ ϋ Φ 0 OJ O α OJ H- φ φ H TJ O φ Φ
3 ft μ- rt o H Ω H < Φ en CO 3 <! 0 3 ii ϋ Ω ϋ ø φ OJ 0 ø d
Ω ø Φ Ω en ø P. φ rt μ- μ- OJ rt rt 3 o μ- μ- μ- φ ? OJ < μ- Φ Ω 0 en PJ ii ii H en TJ o μ- Pi tf O rt TJ en en o ii OJ o rt ø φ μ- 3 φ O H1 μ- T φ o
Φ OJ OJ μ- ϋ 3 rt CO rt Φ ø ^ ϋ Φ Hi ^ Ω ø O μ- 0 ø Φ ø Φ Hi μ- ii ø tr
OJ ø Ω t Φ J ø H- Φ rt en o Pi H- O Φ ft ■Λ H eo μ- en 0 OJ μ- ø Φ rt μ- ft μ- 0 ii en 0 rt en 0 Φ 0 rt 0 ii Ω OJ μ- OJ μ- rt ø 0 rt en OJ Ω Ω tQ Ω 0
Φ 3 J 0 OJ φ 0 rt Φ rt 0 rt Hi Φ Φ Ω ø 0 <! H ø φ tQ ø ii OJ 0 rX
OJ ii en Ji ø 0 Φ CO P. P. μ- μ- 2. rt P. H- tQ ii rt OJ Φ 0 J J 3 0 o
3 H 0 μ- μ- rt a Ω Φ en 3 ø TJ 0 tr OJ rt Ω μ- Hi P. 0 ø 0 tr 0 tQ μ- en P. en φ en tr 0 0 rt 0 en Φ ii Pi φ H P. • tr tr ø 0 μ- en en tr P. ii μ- Ω ^
X - ø rt en μ- 1-3 ø Hi 3 Φ Hi 0 en 0 Φ φ tr μ- OJ φ tQ en rt rt ø Hi Φ rt ø X - rt Ω ø rt t μ- TJ Φ en ii en μ- H- CΩ ø IX φ ϋ OJ μ- if 0 μ- OJ o ø TJ rt 0 OJ <! tr Φ rt 0 3 rt en φ en Hi Pi o ii en (Q OJ rt CO OJ Φ ii rt φ Ω H. 0 rt 0 ii Hi ø φ OJ ii ■g tr C H- tr ø μ- μ- O Φ H-» 0 rt φ < tr 0 en OJ rt OJ 0 ø μ- rt ω
Φ OJ H Pi ø rt Φ φ (0 0 0 φ 0 (Q ø O ø o TJ Φ O μ- Φ Ω φ rt μ- tr ft 0 rt en O en en 0 μ- en rt en i Φ Hi φ Ω ø rt tQ rt ii 0 &* •> ø ii ft Φ ø . — . rt tr ft Ω μ- Ω OJ • o rt H. ii φ μ- μ- μ- Φ μ- ø Ω Φ tQ φ OJ n 3 o Ω t
Hi en ii ii 0 0 OJ H Cd 0 Hi Φ rt en Φ OJ X H, Ω O O ø ii OJ f- g • 0 o J Hi rt OJ ^ —
0 OJ ø ø ø Φ μ 0 0 en tr OJ 0 OJ μ- OJ ø rt Ω OJ ø en • tQ TJ rt en H O 0 ø - ϋ 0 ii Ω • • n rt Φ en en Pi 3 Ω H ^ H Pi Φ O O 0 tQ H1 ϋ OJ
H μ- rt μ- tr OJ TJ rt C φ J OJ O T 0 μ- Hi TJ μ- Φ Φ OJ ø μ- OJ en φ ø ø Ω Φ rt H & φ ct OJ o P. O rt OJ Hi μ- P. Ω i s OJ cn ø μ- ø Pi ø O
Ω 3 en ii OJ tr o Φ X tr ø tr H φ μ- CO Ω φ tr OJ -1 rt Ω rt P. μ- Φ en en > ii OJ OJ rt Φ en H rt OJ φ μ- o 0 en S OJ OJ ft tr tr Φ Ω Ω ø φ O 1
Φ ii OJ 0 3 Ω Φ φ Φ 3 3 OJ en ø OJ o Hi ø Φ Ω μ- Hi 0 o P. ii φ μ- H ii μ- ii OJ μ- X TJ OJ OJ en rt o ; ϋ O tQ O ISl O rt OJ 0 o rt tr
0 ø Φ OJ μ- Ω φ en ø TJ ø . OJ O o en W tr ii Φ Ω 3 O 0 H μ- ø rt tQ Φ ^Ω μ- Φ ø OJ OJ φ rt ii φ μ- en .Q1 Φ tr W Hi μ- Φ en O TJ ii TJ Hi μ- H Φ H - ø Ω OJ (-■ 0 μ- Φ 3 ϊ Ω μ- μ- Ω ø tr Φ 3 O rX rt > 3 o 0 Φ tQ tQ 0 0 H φ rt ø en rt OJ OJ i H ø OJ OJ tQ OJ X μ- 0 0 ii tr OJ H 0 Ω Φ ^-^ ii H 0 H H Pi tf en IX M rt 0 Φ μ- tQ Ω 0 < OJ ø 0 0 r Φ Φ H H ø 0 0 tr tQ tQ μ- μ- ii rt μ- Φ en ii OJ rt rt 3 μ- 3 0 i ΪX ø Φ en o CO Φ 3
K OJ Φ en tr tr tr Φ tr 0 Pi TJ en *< Hi μ- tr Φ O TJ en 0 en Φ μ- Pi OJ Hi ξj* H. O
0 Ω ii H. K Φ Φ ø Φ OJ μ- tr Φ 0 <! φ 3 0 H OJ Pi ϋ OJ Φ Pi 0 tQ μ- OJ O
Hi μ- rt 0 OJ OJ Hi ii Hi μ- Pi OJ ϋ Φ 0 ii Φ μ- rt •> < Hi μ- Φ ø rt
0 co H- Hi fi H OJ P. tr Hi φ Hi ø ø ø H •> P. ft Hi Φ Ω 0 0 OJ Φ . ii 3 0 μ- μ- μ- K. Φ Φ Φ - P. μ- O en * Ω 0 τ3 O > O rt OJ Φ en PJ en 0 Φ φ en Hi OJ <! Ω TJ H. φ ø O Φ Φ tr OJ μ- h O 3 if Ω φ !S
Φ en ø en en Ω Hi μ- Φ rt ϋ Φ O <! 0 Ω 3 J 0 OJ ø OJ Ω 3 N J TJ Φ rt Φ
X s: o • ii φ ø φ 0 0 φ ii i TJ tr ø μ- 0 0) CO tr 3 o μ- CO rt Φ Ω
OJ ϊf 0 ^ Φ ii O Hi rt tr Φ o μ- OJ tQ 3 Φ Φ ø TJ <! ø OJ . 0
3 μ- Hi o ø φ φ tr OJ Hi φ en en OJ OJ 0 ø en ø φ OJ OJ H> O μ- ø 0 ii O Ω ϋ tQ H
TJ o øJ 0 ø * 0 ii rt rt Ω CO 0 0 Ω CO 0 ^ Hi 3 rt Pi Φ rt tr tQ rj1 tr 3 Ω Φ ft μ- rt Pi rt OJ μ- OJ OJ rt Φ Pi OJ Φ • μ- φ en en μ- φ μ-
Φ μ- 0 3 0 ø Hi \ tr tr 3 ø ø μ- pj CO tr PJ μ- 3 μ- Pi ii 0 Φ o rt rt tr 0
OJ Ω 3 H- ii tQ Ω O 0 φ Φ Ω P. < . en μ- ø ω PJ ø Φ Hi rt ø 0 tr •<; O
Hi H H J Ω OJ OJ ii ii ^ Φ μ- 0 Ω 0 en OJ H <! 3 P. tr rt OJ en en
Φ Φ o o OJ rt rt OJ TJ O rt H to H Ω TJ μ- O φ μ- OJ OJ o rt φ tr φ ii 0 ø Φ φ φ Φ Pi en o TJ ϋ •<! ø φ tr OJ O Pi OJ 0 eo rt μ- Hi iQ o
3 0 H 0 J CO tQ X X 3 OJ μ- PL. Ω Φ Φ rt Ω 0 <! rt Φ 3 ø rt ø 3 Pi
Φ en tQ α H H. rt 0 OJ TJ μ- Ω ø μ- OJ O Φ tr ø 3 μ- 0 tr Pi Φ μ- OJ Φ Ω 1 OJ μ- φ o Φ ø φ 0) en μ- 0 ii en
• 3 ø H rt ø Ω Hi 1 μ- μ- 0J 3 Φ 0J CO 1 OJ 0 en ø H 1 rt Pi 0 1 Pi 0 μ- TJ Φ μ- μ- en 1 ø Ω O 1 • Φ 0 O Ω 0
OJ 1 1 Hi Φ en en 1 1 ø Φ 1
1 en • tQ OJ
Φ 1 1 Φ en
Pi Ω ft OJ X if rt i φ Ω 3 3 Ω TJ μ- rt Φ Pi en 0 Ω ø TJ TJ TJ μ- rt o P. ØJ t μ- 3 rt
OJ μ- ii 1 φ OJ μ- OJ μ- ^ μ- ø ii ø tr ii μ- Φ ^ 0 0J ØJ H ii H ø H 0 μ- cn Φ en μ- μ- ø μj o φ ^ H en en OJ o Ω ϋ O tQ Φ OJ en <! H Φ 0 CO o o O tQ 0) rt H 3 o o
(Q ø μ- * ■< Φ Φ rt rt H en ft tr φ Φ Φ φ ft rt rt 0 *< μ- ØJ CO cn ii ø en 3 OJ ø 1 OJ en Φ 0 O O φ rt Φ μ-1 0) H tQ 3 TJ • φ Φ Φ OJ en o . O
OJ 0 en W Cd 3 en Pi ø ft h μ- tr O en ø 0 ii μ- μ- μ- μ. tQ rt ø 3 o O 0)
M ø ii φ 0 ø Φ μ- 0 ø Φ Hi φ 4 rt Φ ø ø ø 0 TJ Φ H 0) μ- Hi π H 0 μ- μ- % P. - μ- 3 ø tr TJ • tr en 0) fl) Hi - ii 0 OJ X o tQ P.
W Hi OJ Φ ^ rt ^ μ- 0 ii CO Ω 0 tQ ft ft Φ μ- O μ- 0 rt TJ 0J
Φ Φ μ-1 3 μ- 3 φ rt TJ 0 O 0) o 3 Φ 0 μ- ii ft o μ- S rt Ω en en ø φ & 0 Φ cn tQ H Φ P. •< IX fi Φ rt •> 0 φ OJ tr 0 n O OJ CO H 0 ^ Φ tQ *< TJ μ- μ- X
Φ rt Φ ø Φ μ- 0 en 0 Φ 0 0 ø ØJ Φ ^ 0 tr H- rt J μ- 0) Φ ø Φ ft ø en rt
• OJ 0 cn rt 3 ø TJ Ω rr rt OJ μ- OJ OJ φ Ω en S H tp iQ Φ ø ø ø H rt . μ- ØJ 3 ii tQ rt Φ 0 OJ φ Hi OJ tr tr Φ O 0 J tr CO P. rt μ- CO μ- • (D O tQ t μ- H- 0 tr & rt m OJ
• μ- rt μ- 0 OJ rt μ- Φ μ- CO - O μ- μ- Φ Ω Ω φ ø ø TJ i o en 3 Ω Φ j Φ 0 Ω
0 μ- rt rt ii rX N ø O ø ^ eo ØJ ii tr o rf ØJ φ 0J rt en tr cn H. 0 rt
Ω ø Ω OJ ii μ- Ω o Pi Ω μ- μ- O μ- Φ μ- ø O ■§ rt Φ 3 ii M J H" 0J tr μ- Φ μ- ii μ-
OJ tr Φ 0) rt TJ φ X"1 μ- ø TJ μ- ft ØJ øj tr φ tr Φ Φ ii φ 0 Φ en *<; øj O
0 o <J H-1 rt - tr <! μ- øj rt 0 Pi tr cn -> tr μ- 0 φ TJ 0 3 O Ω Ω μ- o φ 0
0 Hi OJ Φ OJ PJ Hi ii Φ ø rt φ TJ φ Φ øj Ω ϋ Ω μ- Φ ft rt O 3 ØJ 3 0J X
OJ ii H Hi Φ H Φ OJ Φ tQ ii i CO O 3 Φ Ω o 0J ø 3 φ φ 3 PJ tr φ ii μ- rt O tr μ- Hi Pi OJ 3 o ø o en Pi ii O φ 0 - ø 0 CO o pi 0 1 μ- Pi Tj o rt Φ tQ μ- ii Hi μ- tr OJ 0 OJ 3 Φ 0 μ- TJ Φ OJ rt Ω Ω rt en a i 0 H1 ii ø ii cn <! if o tr OJ en μ- rt H rt μ- 0 ft øj 3 . TJ Φ φ tr φ OJ φ § 0 μ- Ω tr ØJ - Hi μ- Φ o ii 0 H Ω tr
• Ω μ- μ- μ-1 rt 0 - Φ ii μ- TJ • ft i > H ø Φ Φ TJ ø ii co O P. Φ ø ø) ft ii tr o ft o μ- μ- ft ø to 0 3 ø rt μ- tQ μ- tQ & H Φ > O μ- Hi en Ω ii μ- 0
X\ ø tr ø OJ OJ Φ TJ rt OJ rt Φ O ø O rt en μ- 1 0 0 J 3 ø Φ 0J h-> μ- o rt o μ- Φ £ OJ μ- Φ 3 Cd ii en ø O φ ø en ^ CO rt TJ O tQ rt en rt Φ Φ ø if ii cn Hi TJ 0 i μ- Q1 •> - φ PJ cn o Cd OJ 0 X H 0 ii ii Φ μ- ■g φ ^ φ Φ ii rt tr Ω TJ μ- o cn en o P. t ØJ β Pi μ- O μ- tr OJ Φ ii n < rt o rt rt H φ OJ 0 H μ- tQ øJ J rt rt 3 0) -i Φ ø 0 μ- ø rt TJ Φ μ- ϊd Φ μ- ØJ Hi Hi tr f rt μ- μ- rt OJ ø OJ Φ rt 0 H tf μ- φ ø Φ ø φ ø Φ O ø TJ tr Pi ii ii φ μ- Pi φ P. rt 0 H cn ø OJ Φ Φ Φ 0 ø PJ ø Ω μ- ø rt j OJ μ- TJ (Q O φ 0 ^ Φ Φ TJ O tQ μ- Ω μ- cn 0 TJ Φ ø en ø rt rt Φ ø Ω ii tf ø ø h H ø Φ PJ ii en 3
OJ tQ cn rt 3 co o H4 ø H en TJ Φ 3 CO μ- O μ- rt Φ O Φ PJ O O 1 en Φ Ω 0J tr Φ φ μ- μ- tr 3 0 Φ H ø μ- ØJ rt Hi μ- ii i J rt ø Hi φ en Ω 0J 0 0 0 en o H OJ 0 Ω OJ tr Pi P. OJ øJ 0 μ- Ω ØJ cn tr *< ø 0 ØJ ø ø 3 Cd Φ TJ 0 ø Ω en H 3 ft O
< PJ en ø H. Pi Φ μ- μ- ii ft M H ii Φ en 0 ø Ω 0 *< μ- 0 rt ii o ^ TJ CO μ-
Φ φ o φ cn en Φ TJ Φ μ- 0 Φ 0 H TJ φ Pα ft ø 0 ø Ω Ω Φ ø 0 0 tr cn 0 tr 3 P. i φ TJ tr μ- ø rt H H ^ o μ- 1 rt ØJ O ft H- Φ μ- rt H cn o >•
3 ^ - Hi μ- Φ o Φ OJ o rX øj ø ø Φ p. φ rt Hi 0 o Hi O t 0 μ- 0 ø o tQ φ ii
OJ ø 3 3 CO en ø KJ tr • ØJ μ- ø μ- H ø 0 ø TJ - ø φ CO o <J μ- tQ 0J P. TJ ø 3 rt OJ rt μ- Φ φ H- 0 CO DO 0 tQ eo ØJ o rt 0 μ- if μ- ø Φ ø TJ 0 3 rt φ tr μ- 0 ø - rt 5* •<; Cd • TJ φ rt ø tf ui 0 Ω ø 0J TJ en 0) 0 tQ ii μ- o ø) 0J μ- P. Φ TJ α OJ OJ t μ- p ø - 0J φ H ØJ OJ en Φ ~ Hi ft ii rt rt Φ Ω Hi ii 0 o μ- H ≥! ø μ- O 0 3 tQ φ CO H μ- TJ CO Φ μ- μ- en TJ μ- rt ø Ω TJ Φ > OJ rt OJ ø rr Ω ø OJ Φ Pi φ Hi tQ 0 0J o ii CO ø tQ O ^ OJ Ω ø φ OJ OJ Pi ø N 0 0 en 0 μ- CO μ- 0 Φ ii rt ø O 0 Φ (Q Φ 0 cn ii 0 OJ Φ O
P. 3 ft μ- CO Pi TJ tr Hi Φ rt O CO Φ w ø 0 0 OJ rt 0 ø 0 rt Φ 3 ii i φ if en φ OJ tr Φ O tr μ- Ω μ- O en TJ Hi ø Φ M Φ Ω μ- O φ tr Φ TJ tQ O ø ø o TJ TJ ii φ μ- K. φ ø tr Pi Ω O TJ Φ Pi • Φ μ- Hi ø 3 tr o Φ ii
■g 3 cn rt 0 H rX ϋ 3 μ- Φ en H. Ω ØJ tQ ø Φ μ- Φ rt cn * 0 tQ OJ φ co o cn φ μ- μ- φ φ Pi OJ ØJ TJ ø ø μ- Φ rt μ- en φ μ- ø o ø 0 0 0J ii tQ μ- 0 3 ø P ii μ- en ø - H. rt Ω rt Hi μ- ø rt 0 ø Cd Ω OJ 0 rt PJ ø ø H- en 0 μ- 1 Ω OJ en H- en en PJ Φ Φ 0 μ- O φ μ- N H O 0 0 ii en 3 1 0 φ ii 1 Φ ϋ 0 1 1 0 1 J PJ O ø 1 J ^ rt 1 Φ
1 en >< ø 1 i ø en 1
quences encoding microbial virulence factors and harboring at least one mutation affecting expression, activity or regulation of proteins encoded by said genes are preferred. As already mentioned above the present invention also concerns methods for the identification of a disease caused by bacterial mutations or a genetic predisposition thereof. Said methods comprise detecting the presence in a tissue-or blood sample of a subject a muta- tion within a nucleic acid sequence selected from the group consisting of Seq. Id. No .1 to Seq. Id. No. 17 and said sequence is part of a gene of said subject. The method of the present invention is e.g. suitable for the identification of one of the above mentioned diseases. Suitable methods for the identification of said diseases or a genetic predisposition thereof in humans are for example PCR techniques, DNA or gene chips, hybridisation techniques and Ligases chain reaction (LCR) . In a preferred embodiment said method comprises the following steps:
1. Blood or Tissue sample
2. DNA extraction
3. Amplification of at least one Sequence se- lected from the group consisting of Seq.
Id. No. 1 to 17 using flanking oligonucleotide primers
4. Analysis of amplification products by se quencing The sequencing step allows the identification of mutations present in the insertion sequence of interest. The design of the oligonucleotide primers is known to those skilled in the art and can be done using standard software.
Examples
Example 1
Microbial sequences in 3'UTR polyadenylation regions of schizophrenia and dementia genes harbour microbial virulence factors and plasmids
DNA from Borrelia burgdorferi , Chlamydia and other intracellular microbes has inserted into ancestral 3 ' polyadenylation sites of the following candidate neu- rological genes: The central cannabinoid receptor gene (CBl) , Alzheimer disease and other dementia genes, Parkinson disease and myotonic dystrophy (see Seq. Id. No. 1 to 17 and Table 1A to IE) . Most insertions originate from microbial virulence factors, transposable elements and plasmids .
CBl and 5HT1E contain related insertions from B. burgdorferi . The human CBl gene is located at 6ql4, which has been reported as a candidate region for schizophrenia involving a translocation break-point co- segregating with schizophrenia, immediately adjacent to the 5-hydroxytryptamine (5HT1E) gene. The spirochaetal insertion into 5HT1E originated from a B . burgdorferi virulence factor, the flagellar basal-body rod protein (fbrp) , responsible for chemotaxis, locomotion and a sy- ringe mechanism for injection into cells. Through infectious recombination, B . burgdorferi introduced another nucleotide sequence containing pll5 and a polyadenylation site into our ancestral genome. As a result of this recombination, pll5 overlaps with fbrp. The fbrp section on the CBl gene originates from an ancient 5HT1E receptor already containing the spirochaetal insertion and not from a direct transposition of B . burgdorferi onto 6ql4, because the first three nucleotides of the overlapping sequence (see Table 1A) are on 5HT1E, and not on fbrp of B . burgdorferi . Gene conversion is the most likely explanation since CBl and human 5HT1E, on which fbrp is absent, are both located in tandem on 6ql4.
OJ OJ t to I-1 I-1
Lπ o Lπ o LΠ o LΠ
netic knock-out of CBl. The transition of the parasite from arthropod vector to human host is accompanied by significant changes in gene expression, which has practical relevance for prevention, as well. The recently approved vaccine against Lyme disease consists of an immunogenic Osp A, that is expressed by the spirochaetal parasite while in the tick gut, turned off on entry into humans and then expressed again at a late chronic stage. After attachment of an infected tick and initiation of a blood meal, anti-OspA antibodies enter the tick gut and mediate killing of B . burgdorferi .
Example 2 Lateral gene transfer of B.burgdorferi into
5HT1E, gene conversion and homologous recombination with CBl
On the human CBl gene, located within a candidate region for schizophrenia at 6ql4 immediately adja- cent to the 5HT1E ( 5-hydroxytryptamine) gene, a nucleotide sequence of (pll5) originating from B. burgdorferi could be identified (Seq. Id. No. 1) . Another ancestral spirochaetal inclusion on 5HT1E originates from a B. burgdorferi virulence factor, the flagellar basal-body rod protein (fbrp) . It can still be found within the serotonin receptor IE gene (5HTIE) on the mouse (Mus muscu- lus) and rat (Rattus norvegicus) . During phylogeny, multiple recombinations between the spirochaetal fbrp and its pre-inserted fbrp templates have exposed the identi- cal sequences on the complementary strand on the double helix, including adjacent non-microbial nucleotides, to further recombination all over the human genome and a clustering of microbial virulence factors from Chlamydia uridarum iron binding protein, Plasmodiu falciparum rhoptry and Staphylococcus aureus penicilllin binding protein, a specific gene conversion occured (see Fig. 1 and Fig. 2). Through infectious recombination,
B. burgdorferi subsequently introduced pll5 into our ancestral genome resulting in a genetic overlap with fbrp. Containing the poly-A signal (AATAAA) , pll5 thus introduced the code for the translation and actual genetic ex- pression of CBl.
Example 3
No point mutations within the polyadenylation signal (AATAAA)
With the introduction and natural selection of the inserted polyadenylation site, lateral gene transfer have effectively influenced the genetic expression of CBl . Presenting save havens for microbial DNA there are no point mutations on this important signal, for a change in the signal would disrupt the genetic expression of CBl . Suppose the mutually advantageous sequences on the polyadenylation signals recombine again with slightly dissimilar spirochaetal strands, the subsequent mismatch repair mutations will be deleterious for both hosts and parasites . Being located on an important 3 ' regulatory code, whose mutational rate runs slower than the molecular clock of silent point mutations in protein coding regions, microbial sequences are thus better protected from mutations and hence stabilised.
Example 4
DNA of B.burgdorferi underlies the schizo- phrenic genotype
That lateral gene transfer has influenced the evolution of higher eukaryotes, such as mammals is counter-current to established views. B . burgdorferi appears to be excluded from the benefits of the extensive lateral gene transfer between micro-organisms, however, as an intracellular parasite with an incomplete genome B. burgdorferi has a direct access to host genes, which it
exploits for replication, and not to be recognised as foreign, the spirochete depends on its own sequences within the human genome. Through molecular mimicry of fbpr antigens within the host's CD45 leukocyte defence system and a structure homologous to nucleoprotein, B. burgdorferi might, for example, dispose of a protective shield at the DNA and protein level, respectively.
Dissimilarity and mismatch mutations between B . burgdorferi and its pre-inserted human templates may nevertheless occur, resulting from genetically induced variability by virulence factor operons, osp A and B, or, alternatively, from a genomic decay in plasmids (Casjens et al., Mol. Microbiol. 2000, 35, 490-516) borrelia reinfection causing putative mutations in AATAAA. Intrigu- ingly, by a single frame-shift mutation within the original translocase, the same process of genomic decay has apparently incapacitated B . burgdorferi to translocate further genetic templates into its hosts (Casjens et al . , Mol. Microbiol. 2000, 35, 490-516). Whereas point- mutations within the poly-A signal would impair the genetic expression, a change in the adenine content of polyadenylation tail (Alberts et al . , Molecular Biology of the Cell, 1994, Garland Publishing), would alternatively enhance or reduce the ribosomal translation of CBl. Several mutations at an early blastular stage can lead to different (chimeral) expressions of CBl (and perhaps other genes) and account for the reported continuum of major psychoses between schizophrenia and bipolar manic-depression . Dissimilarity and infectious recombination between protein coding sequences of the human chromosome associated protein hCAP and borrelia P115 (63% identities with P115) could, on the other hand, account for the altered leukocyte chromatin ultra-structure reported in schizophrenic patients.
Genetic epidemiology which has provided consistent evidence over many years that schizophrenia has a
t t μ»
Lπ σ LΠ σ Ul σ LΠ rt HI ii Ω TJ μ- tr tQ Hi 0 O TJ TJ rt n Cd cn ^— -* Hi rt tQ Ω Ω μ- Ω
0 1 0 Φ H O ø μ- Φ tr 0 Cd if 0 tr td O Ω 0J 0 Φ Φ μ- Φ O ø O ι-3 ii Ω 0 en en ø 0 g » 0 en Φ ii ø rt ii Pi 0 rt ø 3 cn a rt Φ 0 Pi φ Φ ØJ Φ TJ tr • H μ- H rt Φ tr rt TJ Φ * f S 3 μ- Pi ii rt rt r Φ Φ rt cn (Q Φ 0 - — - cn OJ H ii μ-
Φ μ- 0J ø* ø rt μ- μ- pa en ft a - μ- TJ Φ H en Ω Pi Ω tr 0 Φ rt rt ø
0 μ- tQ rt Φ o Ω - ø $ o O μ- 0 μ- Ω tr O O 0 3 Φ OJ ø) tr Pi ø tr Pi ø tr Φ 3 3 ø (i Φ øj OJ μ- 0J 0 rt 0 φ Pi rt
Pi μ- ØJ ø) Φ en Φ en Φ O ø O OJ 0 N Ω < i 1 ø μ- l_J. ø OJ rt P. Hi X øJ Φ 0 H rt 0 Ω 0 tr 0 0 φ Φ 3 rt Hi 0
0J Hi μ- Ω tr tr TJ μ- rO 0 ø) Hi tr ii 0 PJ en TJ 0 ii 3 μ- øj tr
Ω rt rt ø
O 0) O ϋ φ ii Ω ø Cd tQ rt 0) μ- ii rt ø- rt en μ- Ω ii H en
Φ tr Φ ø Ω TJ rt iTJ φ tr φ • O μ- Cd Φ tQ tQ H μ- H μ- Ω ^ TJ
0 Φ ii en Φ J 3 μ- cn ø 0 0 • rt μ- PJ 0J Φ rt O H o tr ft 0 rt φ tQ CO ø rt tr en ø 0J 0 o rt h-1 0 O ø 0 XX en rt Φ
TJ rt 3 ft Φ Φ Φ 0 μ- O H1 0 ^ tr H ØJ i μ- tr μ- rt Φ rt
0 ii tr μ- 3 ø ii O S •<; H ii 0 rt Hi ^~. tr øj Φ Hi μ- OJ ii 3 ^
0 Φ φ rt 0 φ TJ Φ ø tQ Φ μ- ii μ- Φ φ iϋ Φ • OJ h 0J
0 1 if O ø en ø) TJ Φ
Cd Φ μ- PJ Ω ø tQ ø en ii 0) Ω O μ-1 ø Φ
1 μ- TJ 0 rt ØJ • O ø ø O 0 en PJ Ω μ- rt Hi to tr 3 0 Pi OJ ø
Φ ø 0 ØJ 1 ØJ rt Hi Ω rt ti 9 φ 0 μ-> Hi ^ rt O μ- 0) 0 rt
^ cn μ- ø 3 li Φ tr ØJ O ii Hi iϊr H ϋ 0 H ø ø ø O cπ ø Ω O Φ rt
TJ Φ ø Ω μ- ^ 0 o PJ 0 φ μ- rt Hi en 0 rt en ø Ω rt M PJ H ø tr
O ii rt φ Ω O H ø) Cd Φ P. H ø μ- Φ μ- 3 tr P. φ if ^ Φ O Φ en rt CO ϋ en 0 tQ ø μ> CO ø μ- ØJ ø ii o Φ ø Φ ØJ O rt rt Ω rt ø
Φ Φ 3 0 rt PJ PJ • tQ μ- ø 0) O 0 rt td ø rt tr en α P. 0 H tr ii ØJ O rt Φ TJ μ- •» 0 en ii ø tr Ω μ- Φ OJ TJ rt OJ μ- OJ 0 H NJ tr P. > 0 OJ O Ω TJ < Φ O O Φ P. ø μ-
Ω Hi OJ øj 0 Ω Hi tr φ μ» ø ø ø ØJ μ- μ- φ cπ 0 0 en φ Pi Ω ii
0 tr rt P. Φ φ rt cn rt ø Φ t tQ K Hi rt rt cn O φ O
0 ϋ μ- a cn H en H tr OJ ØJ o . 0 O μ- β μ- rt O H - 0 cn Ω ft TJ 0 a ø O rt μ- if μ- Φ 0) 0 P. rt Ω Ω μ1 H if ø) XX rt tr ϋ 0 0 0 H o XX ø P. Pi cn ø tr ø td en φ O M rt ii ØJ
O O Ω ø) Hi 0 TJ Pi μ- rQ o cπ OJ en rt Cd O Φ ø) Φ
H ø Hi rt a H tr cn O 3 rt H rt W Φ - — - 0 cn H1 ϋ H rt ii Φ if n rt O rt μ- μ- l H3 rt Hi rt vQ ~
0 Φ cπ TJ if a Hi tr OJ en LΠ O 0^ 3 if en O . Hi ØJ if μ> 0 Φ cπ φ tα 3 H- rt tc 0J OJ ØJ φ 3 ø ii M tr rt ii (i ^ ii H1 K
•9 >-3 CO μ- ι-3 OJ rt Pi OJ ØJ O 0 0 tr Φ tr rt μ- ] Hi ø (-» 0) O 1 ø φ tr rt H tr 3 OJ rt rt Φ Φ Ω μ- H3 if X tr φ M Q tr Φ 0 M Pi μ- rt 0 O Ω en Φ ØJ Ω tr Φ td ii ø Φ OJ cn tr 0 ii •< n tr ØJ Φ ØJ li
Hi øJ H i 1 Pi ϋ Φ J TJ ø 3 ø ø tr μ- TJ
Ω ø en ^ ii μ- O O ø PJ cn μ- Φ
Φ H μ- φ Φ rt Φ 0 0! φ ii Φ <! P. OJ rt 0 Ω μ- OJ ϋ ø X OJ en 0 0 0 rt TJ cn Ω CO rt Φ ø Φ μ- PJ ØJ en p. H tr Φ Ω TJ ø
Φ Ω 0 tr Φ rt H μ- μ- TJ μ- H *« rt O Φ Φ OJ φ OJ Ω H 0 PJ
0 Ω Ω φ øJ TJ μ- OJ 0 øJ OJ ø rt φ Φ ø 0 rt cn 0 0 en
Hi O rt 0 Hi rt ii O rt ø μ- Φ tr Ω Ω — rt Φ tr 3 Pi Φ μ-
3 O ii ø μ- Φ Φ 0 μ- rt ii Φ rt o O Hi S μ- O r μ- PJ rt rt TJ H ii X Pi 1 en O en Φ μ- 0 ø tr ø i ii rt φ μ- ø cn tr 0) rt φ rt ^ μ-1 0 μ- 3 3 ø - ft ft ϋ en Φ Φ tr Pi rt
Φ ϋ tr P. if < ii TJ ø tQ tQ 0 rt 4 li OJ rt TJ en (Q ØJ if TJ μ- ^ φ μ- Φ øJ ø H rr 0 0 0J μ- tr 3 μ- M rt rt OJ φ i en en 3 tr H. ø Φ Ω 0 0) ØJ OJ 0 0
0 ø φ O ø O O 0 μ- PJ Φ
OJ O μ- φ 1 X Pi rt ft 1 en μ- Hi 1 ø Ω O I
3 ø ø 1 1 3 φ μ- 1 J ØJ ø 0J φ 1 ø O
1 tQ 1 1
0 TJ TJ Ω ØJ 0 0) tr
Hi 0 ii 0 pj Ω O ii ro 3 Ω
H rt ø Φ 0 Φ μ-
0 Φ ØJ ft ii ii N
Hi PJ rt μ- cn rt O
Φ 0) ø μ- μ- ø
Ω μ- H Hi X J Ω rt rt ø φ O ø ØJ OJ μ- to Ω μ- ii
0 if rt Pi μ- ø ø μ- ø rt rt en 3 tr o rt tQ ii ii
ØJ c ø μ- ØJ OJ α ø ii en Ω rt ø ø μ- ^ rX tr en en en tr Ω_ $ φ 3 Hi φ Φ 0 μ- μ- μ- φ
OJ μ- K. rt ø rt en Ω en ø Hi if rt H cn rt φ tQ Φ o O OJ μ- μ- en en H. ø ø 0 O
• μ. rt Φ en ø ø
—. tQ 3
TJ to μ- TJ (Q μ- 0 0 tr rt ø H en en Hi Hi μ- Φ Hi μ- cn
Φ φ O 0) μ- rt tQ
ØJ ii Ω ii ø o if φ i φ rt PJ ø Φ li φ μ- tr 3 μ- 0 H 0 PJ
TJ 0 0 0 OJ Hi μ- tr O H eo μ- μ- TJ tr Pi <! to φ ø ø) ii 0) ØJ ØJ Φ
• • μ- < 3 φ CO ø Φ Φ tr φ Ω
O Ω ØJ c • φ if H- μ- 3 i H1
0 TJ ø - tr <Q >-3 M
H H P. μ- Pi if CO
Ω Φ Φ OJ Ω o μ- tr en φ ø tr ii en μ- 2
Pi Pi Hi - 0
H ø) Ω ro 0
H ø tr cn 0) ii μ- H
PJ Φ TJ 0 μ. ø PJ tr1 Φ 0 μ- TJ ø ii rt Hi Hi
<! ii OJ tr ii 0) Φ μ- ØJ ii P. 0 O Ω OJ ø Ω φ μ- cn 3 rt Pi tQ rt i Ω ^
1 μ- tr rt rt
Ω φ tr 0
Φ 1 Φ
stone, 2000, 2504-2518) . By adding genetically vulnerable cases to the population human germ-line transfection by B . burgdorferi would thus explain the continued presence of schizophrenia at high prevalence, despite the fact that the disease confers reduced procreational fitness and fertility.
The association between level of cannabis consumption and development of schizophrenia during a 15- year follow-up was studied in a cohort of 45,570 Swedish conscripts . The relative risk for schizophrenia among high consumers of cannabis (use on more than fifty occasions) was 6.0 (95% confidence interval 4.0-8.9) compared with non-users. Persistence of the association after allowance for other psychiatric illness and social back- ground indicated that cannabis is an independent risk factor for schizophrenia (Andreasson et al . , Lancet 1987 Dec 26; 2 (8574:1483-6) .
Example 5
Significant CBl-Dl protein homology versus CB1-D2 nucleotide homology
There are significant homologies, which cannot be reduced to lateral gene transfer. CBl shows sig- nificant homology with the dopamine Dl - a type I G- protein coupled receptor - at the amino-acid level (Score = 71.0 bits (171), Expect = 2e-ll, Identities = 75/320 (23%), Positives = 137/320 (42%), Gaps = 50/320 (15%) (Online Mendelian Inheritance in Man, OMIM 2000, Center for Medical Genetics, John Hopkins University
(Baltimore, MD) and National Center for Biotechnology Information, (Bethesda, National Library of Medicine, 2000) . Other homologous proteins comprise G-protein coupled receptors that receive information from outside the cell, such as olfaction or vision. However, owing to one specific sequence of 19 homologous base pairs at the nucleotide level, it is the dopamine 2 receptor (D2) - a
type II G-protein coupled receptor - which shows significant DNA homology to CBl (Score = 37.2 bits (19), Identities = 19/19 (100%) . The circumscribed homology between CBl and the D2 receptor, which is an important phar acol- ogical target for the treatment of schizophrenia, encodes the seventh transmembrane loop which is known for its inhibitory-mode (i-mode) of metabotropic action. Apart from a silent point mutation from GTG to GTC in the rat D2 receptor gene (Rattus norvegicus) , which has occurred after the phylogenetic rat mouse divergence 35 million years ago, this homologous nucleotide sequence can be found an all sequenced primate (Macaca mulatta, Cercopithecus aethiops, H. sapiens; OMIM, 2000) and rodent (Mus muscu- lus) D2 receptor genes. An early prenatal event interfering with neu- ronal migration from inner to outer cortical laminae in mid pregnancy most likely underlies the consistent pattern of cellular disarray observed in schizophrenic brains. If the expression of higher levels of CBl within outer cortical compared to inter-cortical layers (Glass et al., 1997, Neuroscience, 77, 299-318) resulted from a CBl mediated migration of neurons, the inter-cortical disarray could be explained by a knock-out of CBl, whose metabotropic i-mode has recently been reported to be cru- cial for cellular migration (Song and Zhong, Journal of Pharmacology and Experimental Therapeutics, 2000, 294, 204-209) . The distribution of CBl, furthermore, exactly mirrors the macro-anatomic regions mainly affected in schizophrenia (Schultz and Andreasen, 1999, Lancet, 353, 1425-30) .
Through a dysinhibition of the i-mode, spatial memories (hippocampal long-term potentiation) of CBl knock-out mice are enhanced (Bohme et al . , 2000, Neuroscience, 95, 5-7) and goal directed, temporal memories decreased. This mnemonic effect, however, not only parallels the pattern of spatio-temporal distortions in schizophrenia. Despite the fact that patients with Alz-
heimer's dementia and tertiary neurosyphilis do hallucinate, they apparently do not remember, or reconnect their hallucinations with a fixed delusion. The difference between dementia praecox (schizophrenia) and syphilitic de- mentia is that without memory hallucinations are lost, and that the thoughts of schizophrenics are flooded with fixed hallucinations, expanding into overt delusions. Furthermore, CBl knock-out mice do show reduced exploratory, goal-directed behaviours (Steiner et al . Proc. Natl. Acad. Sci. USA, 2000, 96, 5786-5790); symptoms that appear to be among the most robust indices in schizophrenia. Without time-bridging working memory, no creative speech and no logical thinking would be possible. A disruption of CBl, which reaches its highest levels in the left-hemispheric area of Wernicke, would thus account for the impairment of goal directed behaviour and speech - the highest form of sequential behaviour in man - being more stereotyped in schizophrenic patients than in healthy persons.
Example 6
The phylogenetic traces of microbial insertions into the human genome were investigated and the gene- tic mechanism were analysed, by which bacterial virulence factors and mobile elements from intracellular parasites could disrupt candidate genes for schizophrenia and dementia. This was done by co-incident DNA homology BLAST searches between neurotropic microorganisms, the central cannabinoid receptor CBl, and other known dementia genes, whose complete sequences with 3'UTR and polyadenylation signals are entered on Gene-Bank databases. Several such genes have now been characterised including those of ApoE4 Alzheimer Disease type II (AD2) and presenilin 2 (AD 4) . Positional cloning and sequencing has also been carried out in other dementias including Familial British Dementia (with mutations in the gene for integral membra-
ne protein 2A) , Hereditary Multi-infarct Dementia (Notch- 3 gene) , primary X-linked mental retardation (oligo- phrenin 1 gene) , Frontotemporal Lobe Dementia, Autosomal Dominant Parkinson Lewy-Body Dementia and Familial Par- kinson disease type I (with mutations in the alpha synuclein gene) . The genomic facilities used are accessible at Online Mendelian Inheritance of Man (OMIM) and very much recommended to anybody interested in applied medical genetics . While there are shown and described presently preferred embodiments of the invention, it is to be distinctly understood that the invention is not limited thereto but may be otherwise variously embodied and practiced within the scope of the following claims.
Genes Organism Sequence Seq. Id. No.
& Events
Table 1A SCHIZOPHRENIA
CBl 1st & 2nd borrelia integrations into ancestral 5HT-CB1 and introduction of poly-A signal
Borrelia (fbrp) (357) CATTTCTTCAACTAAATTAACATT ( 33 ) 5 ' 18 5HT1E/ AttCATTTCTTCAACTAAATTAACATT 19
CBl ( anc .1) AttCATTTCTTCAACTAAATTAACATT
6ql4 Borrelia (P115)(4133) GATTCAAATAAAAATTCTAAATTACCAT (4160) 3 ' 1
Chlamydia integration into ancestral rodent CBl Chlamydia (8221) TTACCTGGACTCAAATAAAAGT(8242) 3 ' 20
CBl (anc.2) (ibp) GAATCAAATAAAAATTCTAGATTACCATgaagaacata 22
CBl (rat) (5430) TTACCTGGAATCAAATAAAAGTTCTAGATTATCACg (5465)3' 21
Chlamydia uridarum integration into ancestral primate CBl
Chlamydia (8219) AGTTACCTGGACTCAAATAAA ( 8240 ) 3 ' 2
CBl (anc.2) (ibp) GAATCAAATAAAAATTCTAGATTACCATgaagaacata 22
CBl (human) /6ql4 (5484) AGTTACCTGGAATCAAATAAAAATTCTAGATTACCATgaagaacata(5530) 47
Chlamydia (1063) AGTTTAATAAAGATT (1049)5' 4
Apo E (anc.) GTTTAATAAAAATT 50
Apo E (4611) AGTTTAATAAAGATTca(4627)3' 27
borrelia infection - predicted mutations by virulence factors
Borrelia (acrB) (8106) TTTAAAAAAGATTCA (8120)3' 28
Borrelia (comp.loc) (11560) TTTAAAAAAGATTCA (11546)5' 28
PRESENILIN 2 (PS2) - Alzheimer's disease type 4 (AD4)
Borrelia burgdorferi (sgp) stability governing protein integrated within presenilin 2 and possible predicted mu- tation by Borrelia reinfection
Borrelia (sgp) (10599) ATACTAATATCAATAA (10614)3' 5
PS 2 (1651) ATACTAATATCAATAAa(1667)3 ' 29 Borrelia (sgp) reinfection (10599) ATACTAATATCAATAA (10615) 3 ' 30
AMYLOID PRECURSOR PROTEIN (APP) Alzheimer's disease type 1 (protease nexin-II)
No Borrelia but has Plasmodium falciparum inclusion and Salmonella typhimurxum transposable plasmid
APP (3547) TTTTCATGTAAATAAATACATTCT(3570)3' 31 Salmonella plasmid traJ (425) TGTAAATAAATACATTCT(442) 3 ' 48
Plasmodium chromosome 3 (79642) TTTTCATGTAAATAAATA (79625)5' 6
(hypothetical protein) (141360) TTTCAGGTAAATAAATA (141344)5' 32
■
FAMILIAL BRITISH DEMENTIA (xntegral membrane protexn 2B gene) Borrelxa burgdorferi Ixnear plasmxds lp25, lp36 and Plasmodium falσiparum major merozoite surface & receptor binding protein
FBD (1753) GATTTTTTCTTTAAATAAAAATAAGT(1778)3' 33
Borrelia lp25 plasmid (18048) TTTAAATAAAAATAAG (18032) 5 ' 7
Borrelia Ip 36 plasmid (9312) TTTAAATAAAAATAAG (9327)3' 51
Plasmodium (mmsp) (1083) TTTTTTTTTTAAATAAAAATA (1103)3' 34
Plasmodium (pfempl) (4682) GATTTTTTCTTTAGATAAAAATAAG (4658)5' 8
Oligophrenin 1 (OPHNl)
Borrelia burgdorferi inclusion from tryptophanyl-t-RNA synthetase
OPHN 1 (6648) CAAATAAAGTAGTAAAAGA (6666) 3V 56
Borrelia (trsa) (101) CAAATAAAGTAGTAAAAGA (83) 5 17
HEREDITARY MULTI-INFARCT DEMENTIA (NOTCH 3 gene)
No Borrelia or plasmodxum, but has vibrio cholera virulenenσe factor and Clostrxdxum insertion
DHMI (8048) CCTAATAAAGGAATAGTTAAC (8068)3' 35
Vibrio (ntno) (4641) AATAAAGGAATAGTTAA (4657)3' 52 Clostridium (ctfA) (2544) CCTAATAAAGGAATAG (2559)3' 53
FRONTOTEMPORAL LOBE DEMENTIA (gene for microtubule associated protein tau)
No Borrelia or plasmodium, but has Staphylococcus aureus antxbxotxc resxstance plasmid
MAP Tau (2276)GCTAGTAATAAAATAT(2291)3' 36
Staph. Plasmid pS194 (2276) GCTAGTAATAAAATAT (2291) 3 ' 36
PARKINSON DISEASE
AUTOSOMAL DOMINANT LEWY BODY (PDLBD) (alpha synuclein gene) Borrelia burgdorferi inclusion from linear plasmid lp36
PDLBD
2nd poly A signal (1521) ACAATAAATAATATTC (1536) 3 ' 37
Borrelia lp36 (13825) ACAATAAATAATATTC (13810) 5 ' 9
PARKINSON DISEASE, FAMILIAL TYPE I (PDl) (alpha synuclein gene)
Borrelia burgdorferi linear plasmid lpl7, Plasmodium falciparum plasmid and Escherichia coli pilus protein PD - 1
3rd poly A signal (952) TAATAATAAAAATCATGCT (971) 3 ' 49
Borrelia lpl7 plasmid (9683) TAATAATAAAAATCAT (9668)5' 10 Plasmodium plasmid (10913) AATAATAAAAATCATG (10928)3' 12
Escherichia (pilus protein) (860) AATAATAAAAATCATGCTT(878) 3 ' 11
Table 1C
MYOPATHY
MYOTONIC DYSTROPHY, 3' UTR & TRIPLET REPEAT
Borrelia burgdorferi and Chlamydia muridarum integration into human myotonxn protein kinase (Mt-PK)
Borrelia (fbrp) (194) TCCGGAATAAAAGGCCCT(177) 5 ' 13
(Mt-PK, anc.) TCCGGAATAAAAGGCCCT 38
(Mt-PK) (2462) TCGCGAATAAAAGGCCCT(2479)3 ' 39
Chlamydia (3551) GCGAATAAAAGGCCCT (3536) 5 ' 14
Table 1 D
GLOBIN GENES - CONTROLS FOR MICROBIAL INSERTIONS β-globin (chromosome 11) β-globin chain versus β-thalassaemia
Poly-A cleavage site (1736 - 1737)
Normal β-globin (1711) AATAAAAAACATTTATtttcattgca atgATGTATTTAAATta (1753) .. 40
Rickettsia (232700) AATAAAAAACATTTAT (232685) 5 ' 15 Borrelia (oppAIV) (1143) ATGTATTTAAAT (1132) 5' 41
normal β- globin ;i754) tTTCTGAATATTTTACTAAAAA ( 1775 ) 3 ' 42 Borrelia (ospC) (364) TTCTGAAGATTTTACTAAAA (384)3' 43
β-Thalassaemia ( 1748 ) AATAAGAAACATTTATTTtcattgca ( 1773 ) 3 ' 44 Plasmodium falciparum (470) ATAAGAAACATTTATTT (486)3' 45
α-globin (chromosome 16) α-globin chain (NM_000558) in lower case letters versus Plasmodium bergei (L21708) within 3' α-globin in upper case letters 46
α-1 and α-2 1 actcttctgg tccccacaga ctcagagaga acccaccatg GTGCTGTCTC CTGCCGACAA 61 GACCAACGTC AAGGCCGCCT GGGGTAAGGT CGGCGCGCAC GCTGGCGAGT ATGGTGCGGA 121 GGCCCTGGAG AGGATGTTCC TGTCCTTCCC CACCACCAAG ACCTACTTCC CGCACTTCGA 181 CCTGAGCCAC GGCTCTGCCC AGGTTAAGGG CCACGGCAAG AAGGTGGCCG ACGCCCTGAC 241 CAACGCCGTG GCGCACGTGG ACGACATGCC CAACGCGCTG TCCGCCCTGA GCGACCTGCA 301 CGCGCACAAG CTTCGGGTGG ACCCGGTCAA CTTCAAGCTC CTAAGCCACT GCCTGCTGGT 361 GACCCTGGCC GCCCACCTCC CCGCCGAGTT CACCCCTGCG GTGCACGCCT CCCTGGACAA 421 GTTCCTGGCT TCTGTGAGCA CCGTGCTGAC CTCCAAATAC CGTTAAGCtg gagcctcggt 481 ggccatgctt cttgcccctt gggcctcccc ccagcccctc ctccccttcc tgcacccgta 541 cccccgTGGT CTTTGAATAA AGTCTGAGTg ggcggc 3 '
Table IE
VIRULENCE FACTORS AND OTHER MICROBIAL INSERTIONS
Borrelia burgdorferi (pll5) : related to human chromosome associated protein responsible for DNA and intracellular movement .
Borrelia b. (fbrp): flagellar basal rod protein for extracellular movement , chemotaxis , syringe mechanism for cell injection.
Borrelia b. (ospA) : outer surface protein A, antigen of genetically induced variation.
Borrelia b. (plasmid lp28-l) : pseudogene on linear plasmid size 28, group 1, being the result of genomic decay.
Borrelia b. (lip P) : lipoprotein P (homologous sequences on plasmids, i.e. Ip38), anti-genetic surface protein.
Borrelia b. (acrB) .-acriflavine resistance protein.
Borrelia b. (comp. loc) : competence locus with multiple homologous copies throughout genome. Borrelia b. (sgp) : stability governing protein for stabilisation of membrane.
Borrelia b. (oppAIV) : oligopeptide permease; immediately adjacent to 3 'poly-A cleavage site of (globin.
Borrelia b. (ospC) : outer surface protein C; 18 base pair distant from 3' poly-A cleavage site of (globin. Target of Borrelia vaccine.
Borrelia b. (pus) : pseudo uridylate synthase Borrelia b. (slipp) : surface lipoprotein p27
Borrelia b. (trsA) : tryptophanyl t-RNA synthetase
Borrelia garini (ospA) : outer surface protein A. Chlamydia muridarum (ibp) within CBl: iron binding protein to overcome host barriers of low iron levels .
Chlamydia m. within Mt-Pk: phosphocarrier protein. Chlamydia pneumonae: hypothetical protein.
Clostridium beijerinckii (ctfA): small subunit of coenzyme A transferase.
Escherichia coli pilus protein: responsible for cellular adherence and infection.
Plasmodium bergei within ( globin series: phosphoprotein mRNA.
Plasmodium falciparum within CBl: rhoptry associated protein (264) ATCAAATAAAAGTTCTA ( 280 ) 3 ' for erythrocyte penetration. Plasmodium f . within amyloid precursor protein: several sequences form chromosome 3 including hypothetical pro- teins .
Plasmodium f. (mmsp) :major merozoite surface protein, expressed during sexual stage.
Plasmodium f. (pfempl) : Plasmodium falciparum-encoded protein on the surface of infected erythrocytes mediates receptor binding.
Plasmodium f . in thalassaemia (globin: RNA polymerase III. Rickettsia prowazekii in (globin: proline-betaine transporter for the reduction of osmotic stress in host environment .
Vibrio cholerae (ntno) : Na+-translocating NADH-ubiquinone oxidoreductase enzyme complex involved in flagella rotation.
Microbial virulence factors within the 3' genetic hotspot of human disease. Base pairs originating form the late- ral gene transfer of microbial nucleotides are indicated in upper case, and non-microbial nucleotides in lower case letters. There are normally no point mutations on the polyadenylation signal, whose non-redundant code protects the microbial inclusions from mutations. Homologous recombination between B. burgdorferi pll5 and the bor- relia template fbrp originating from ancestral 5HT1E has introduced the polyadenylation signal AATAAA into CBl. Note that recombinational mismatch-repair has inserted an additional adenine into CBl. A point mutation from A to G has through a reduction of the adenine content led to a shortening of the 3' polyadenylation tail of the rat. Within human CBl and rat CBl, almost identical, but independent insertions of C. muridarium nucleotides must have occurred twice. This reoccurrence emphasises the attraction CBl and its polyadenylation signal exerts on microbi- al DNA to recombine . In the case of dissimilarity (i.e. AATATA) mismatch repair mutations might, in analogy to the genetic knock-out of globin in thalassaemia, result in a knock out of CBl and other neurological candidate genes .
3rd borrelia infection - predicted mutations by vxrulence factor or plasmid of human CBl poly-A signal
Borrelia burgdorferi (ospA) (41) ATAATAATTCTAAATTA (25 ) 5 ' 24 Borrelia garinii (ospA) (229) ATAATAATTCTAAATTA (213) 5' 23
Borrelia (plasmids ;"i .e. Ip28-1) (7553) AATATAAATTCTATAT (7568)3' 25
Microtubule associated protein 2C (MAP2C)
Borrelia burgdorferi inclusion from pseudouridylate synthetase MAP2C (3634) AAACTCAGAAAATAAAATGT 3λ (3653) 54
Borrelia (pus) (2645) AAACTCAGAAAATAAAATGT 5l (2626) 16
Borrelia (slipp) reinfection (40665) CAGAAAATAAAAT 5 (40653) 55
Table IB
DEMENTIA
APOLIPOPROTEIN E (Apo Ξ) Alzheimer's diease type 2 (AD2)
Borrelia burgdorferi surface protein integrated within ancestral ApoEe4
Borrelia (lipP) (11) GTTTAATAAAAATT(24) 3' 3
Apo E (anc . ) GTTTAATAAAAATT 26
Chlamydia pneumoniae integration into ancestral ApoEe4
Claims
1. Use of a DNA sequence comprising a frag- ment of a nucleic acid encoding a putative microbial virulence factor as means for the identi ication of a disease caused by mutations or a genetic predisposition thereof .
2. Use of claim 1 wherein said virulence fac- tor is located on a linear or cirular chromosome or a plasmid.
3. Use of claim 1 or 2 wherein said virulence factor stems from a intracellular microorganism.
4. Use of claim 1 or 2 wherein said virulence factor stems from a non-intracellular pathogen and is part of a cluster shared by intracellular microorganisms.
5. Use of claim 1 wherein said microorganism is selected from the group consisting of Borrelia species, Chlamydia species, Escherichia sp., Plasmodium spe- cies and Rickettsia species.
6. Use of anyone of claims 1 to 5 wherein said fragment is selected from the group consisting of Seq. Id. No. 1 to Seq. Id. No. 17.
7. Use of anyone of claims 1 to 4 wherein said sequence comprises a mutation, either caused by by the same or a different species, preferably within the polyadenylation signal sequence.
8. Use of anyone of claims 1 to 7 wherein said disease is a human disease.
9. Use of claim 8 wherein said human disease is selected from the group consisting of schizophrenia, Alzheimer disease, Parkinson disease, Myopathy and other forms of dementias .
10. Use of claim 8 wherein said human disease constitutes a predisposition or a genetic variation, the pathological manifestation of which is triggered by medicaments or drugs .
11. Use of claim 10 wherein said drug is cannabis .
12. Use of claim 11 wherein said pathological manifestation comprises any form of dementia, schizophre- nia, or related psychatric disorders.
13. A method for the identification of a disease or a genetic predisposition thereof, which comprises detecting the presence in a tissue-or blood sample of a subject a mutation within a nucleic acid sequence se- lected from the group consisting of Seq. Id. No .1 to Seq. Id. No. 17 and said sequence is part of a gene of said sub ect .
14. The method of claim 13 wherein said tissue sample is a foetal graft for neurotransplantation.
15. The method according to claim 13 or 14, wherein said sequence is inserted in the 3'UTR of said gene .
16. The method according to anyone of claims 13 to 15, wherein said mutation is found in the polyade- nylation signal of said gene.
17. The method according to anyone of claims 13 to 16, wherein said mutation affects the expression of the protein encoded by said gene .
18. The method according to anyone of claims 13 to 17, wherein said gene is selected from the group consisting of Cannabinoid receptor 1 gene, MAP 2C gene, apolipoprotein E gene, presenilin 2 gene, integral membrane protein 2B gene, , alpha synuclein gene, oligo- phrenin 1 gene and myotonin protein kinase gene.
19. A transgenic non human animal whose genome comprises a partially or completely inactivated endogenous gene as defined in claim 18, wherein said inactivation is due to at least one mutation in its 3 ' untranslated region, said mutation leading to inhibition or suppression of the subsequent gene translation.
20. The transgenic non-human animal of claim 19, wherein the mutation is located in the nucleic acid sequence following the polyadenylation signal, more preferably in the polyadenylation sequence of said gene.
21. The transgenic non-human animal of claim 20, wherein said mutation is a point mutation.
22. The transgenic non-human animal according to anyone of claims 19 to 21, wherein said animal is a mammal, in particular a rodent.
23. The transgenic non-human animal of claim 22, wherein said animal is a mouse or a rat.
24. The transgenic non-human animal according to anyone of claims 19 to 23, wherein said inactivation is a homozygous or a heterozygous inactivation.
25. Use of a transgenic non-human animal according to anyone of claims 19 to 24 for the identifica- tion of compounds that have an effect on the activity, expression or regulation of the translated protein.
26. A method of screening compounds that have an effect on the activity, expression or regulation of a protein encoded by a gene according to claim 18 compris- ing introducing a compound in an animal according to anyone of claims 19 to 24 and monitoring behavioural changes in said animal as compared to a control animal .
27. Use of a transgenic non-human animal whose genome comprises a non-functional endogenous CBl gene for the identification of compounds that have an effect on the activity, expression or regulation of CBl protein.
28. A DNA and/or RNA chip comprising at least one of the nucleic acid sequences selected from the group consisting of Seq. Id. No. 1 to Seq. Id. No. 17.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB0001127 | 2000-08-16 | ||
WOPCT/IB00/01127 | 2000-08-16 | ||
PCT/IB2001/000189 WO2002014546A1 (en) | 2000-08-16 | 2001-02-15 | Use of microbial dna sequences for the identification of human diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1309722A1 true EP1309722A1 (en) | 2003-05-14 |
Family
ID=11003962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01902591A Withdrawn EP1309722A1 (en) | 2000-08-16 | 2001-02-15 | Use of microbial dna sequences for the identification of human diseases |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1309722A1 (en) |
JP (1) | JP2004506429A (en) |
AU (1) | AU2001230448A1 (en) |
CA (1) | CA2418087A1 (en) |
WO (1) | WO2002014546A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996034099A2 (en) * | 1995-04-28 | 1996-10-31 | Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease, and uses therefor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998058943A1 (en) * | 1997-06-20 | 1998-12-30 | Human Genome Sciences, Inc. | Borrelia burgdorferi polynucleotides and sequences |
-
2001
- 2001-02-15 EP EP01902591A patent/EP1309722A1/en not_active Withdrawn
- 2001-02-15 WO PCT/IB2001/000189 patent/WO2002014546A1/en not_active Application Discontinuation
- 2001-02-15 AU AU2001230448A patent/AU2001230448A1/en not_active Abandoned
- 2001-02-15 CA CA002418087A patent/CA2418087A1/en not_active Abandoned
- 2001-02-15 JP JP2002519671A patent/JP2004506429A/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996034099A2 (en) * | 1995-04-28 | 1996-10-31 | Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease, and uses therefor |
Non-Patent Citations (1)
Title |
---|
See also references of WO0214546A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001230448A1 (en) | 2002-02-25 |
JP2004506429A (en) | 2004-03-04 |
WO2002014546A1 (en) | 2002-02-21 |
CA2418087A1 (en) | 2002-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Meister et al. | Anopheles gambiae PGRPLC-mediated defense against bacteria modulates infections with malaria parasites | |
Donelson | Antigenic variation and the African trypanosome genome | |
Gardner et al. | Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum | |
Klingbeil et al. | Multiple mitochondrial DNA polymerases in Trypanosoma brucei | |
Shirasu et al. | A novel class of eukaryotic zinc-binding proteins is required for disease resistance signaling in barley and development in C. elegans | |
Faruque et al. | Genomic analysis of the Mozambique strain of Vibrio cholerae O1 reveals the origin of El Tor strains carrying classical CTX prophage | |
Ding et al. | Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function | |
Suarez et al. | Structure, sequence, and transcriptional analysis of the Babesia bovis rap-1 multigene locus | |
Benne | Mitochondrial genes in trypanosomes | |
AU2003245488A8 (en) | Functional sites | |
Campo et al. | Differential accumulation of mutations localized in particular domains of the mucin genes expressed in the vertebrate host stage of Trypanosoma cruzi | |
Sun et al. | Kirrel2, a novel immunoglobulin superfamily gene expressed primarily in β cells of the pancreatic islets☆ | |
Luckhart et al. | Transcriptional complexity of the Anopheles stephensi nitric oxide synthase gene | |
Simões-Barbosa et al. | Hitchhiking Trypanosoma cruzi minicircle DNA affects gene expression in human host cells via LINE-1 retrotransposon | |
Sahoo et al. | Cloning, nucleotide sequence and phylogenetic analyses, and tissue-specific expression of the transferrin gene in Cirrhinus mrigala infected with Aeromonas hydrophila | |
JP4675330B2 (en) | Charcot-Marie-Tooth disease type 2A detection method | |
WO2002014546A1 (en) | Use of microbial dna sequences for the identification of human diseases | |
Li et al. | Analysis of Chlamydomonas reinhardtii Genome Structure Using Large‐Scale Sequencing of Regions on Linkage Groups I and III | |
Müller et al. | Stage-specific expression of the glycine cleavage complex subunits in Leishmania infantum | |
US20040101867A1 (en) | Use of microbial dna sequences for the identification of human diseases | |
Bonaldo et al. | 1274 full-open reading frames of transcripts expressed in the developing mouse nervous system | |
Amirian et al. | Detection of a new KCNQ 1 frameshift mutation associated with Jervell and Lange‐Nielsen syndrome in 2 Iranian families | |
US6756228B2 (en) | Atherosclerosis susceptibility gene locus 1 (Athsq1) and atherosclerosis susceptibility gene locus 2 (Athsq2) | |
Wang et al. | Identification of differentially expressed genes in Oncomelania hupensis chronically infected with Schistosoma japonicum | |
Campesan et al. | Comparative analysis of the nonA region in Drosophila identifies a highly diverged 5′ gene that may constrain nonA promoter evolution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030110 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17Q | First examination report despatched |
Effective date: 20040907 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060503 |